Clinigen Group PLC | |
Stock Exchange | Other OTC |
EPS |
$0.27 |
Market Cap |
- |
Shares Outstanding |
115.37 M |
Public Float |
- |
Clinigen Group PLC | |
Stock Exchange | London Stock Exchange |
EPS |
GBP20.07 |
Market Cap |
GBP1.3 B |
Shares Outstanding |
132.48 M |
Public Float |
119.37 M |
Address |
Pitcairn House Burton-on-Trent Staffordshire DE14 2WW United Kingdom |
Employees | - |
Website | http://clinigen.co.uk |
Updated | 07/08/2019 |
Clinigen Group Plc engages in the provision of pharmaceutical products and services. It operates through the following segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA), Clinigen Specialty Pharmaceuticals (SP), and Link Health Care. The Clinigen CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. |